Biotech Values

[stockbettor]

Her's a link to Synthon's PIII trial presumably needed for European approval:

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
This study is currently recruiting participants.
Verified on December 2011 by Synthon BV


First Received on December 8, 2011. No Changes Posted
Sponsor: Synthon BV
Information provided by (Responsible Party): Synthon BV
ClinicalTrials.gov Identifier: NCT01489254

Purpose
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis

http://clinicaltrials.gov/ct2/show/NCT01489254